United Kingdom · Question · Written question
UIN 1452
Ivacaftor/tezacaftor/elexacaftor
Original
Introduced
8 January 2020
Last action
17 January 2020 · Answer
Status
Answered
Sponsors
—
Subjects
Discovery layer
Source updated
17 January 2020
Summary
To ask the Secretary of State for Health and Social Care, what assessment he has made of the (a) effectiveness and (b) availability of the drug Trikafta for people with cystic fibrosis.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
8 January 2020
Written question
To ask the Secretary of State for Health and Social Care, what assessment he has made of the (a) effectiveness and (b) availability of the drug Trikafta for people with cystic fibrosis.
Source: Commons
17 January 2020
Answer
The Department has made no such assessment. Elexacaftor, tezacaftor and ivacaftor combination therapy (or triple therapy, marketed in the United States as Trikafta) does not yet have a marketing authorisation for use in the United Kingdom and the dates fo...
Source: Written answer
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
- · Department of Health and Social Care · Answering body
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://questions-statements.parliament.uk/written-questions/detail/2020-01-08/1452
- Open data entity: https://questions-statements-api.parliament.uk/api/writtenquestions/questions/1169614
- uk · wq-1169614 · source updated 17 January 2020